PURE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PURE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PURE Bioscience's change in receivables for the quarter that ended in Jan. 2024 was $0.18 Mil. It means PURE Bioscience's Accounts Receivable declined by $0.18 Mil from Oct. 2023 to Jan. 2024 .
PURE Bioscience's change in receivables for the fiscal year that ended in Jul. 2023 was $-0.08 Mil. It means PURE Bioscience's Accounts Receivable increased by $0.08 Mil from Jul. 2022 to Jul. 2023 .
PURE Bioscience's Accounts Receivable for the quarter that ended in Jan. 2024 was $0.17 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. PURE Bioscience's Days Sales Outstanding for the three months ended in Jan. 2024 was 47.86.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. PURE Bioscience's liquidation value for the three months ended in Jan. 2024 was $-1.68 Mil.
The historical data trend for PURE Bioscience's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PURE Bioscience Annual Data | |||||||||||||||||||||
Trend | Jul14 | Jul15 | Jul16 | Jul17 | Jul18 | Jul19 | Jul20 | Jul21 | Jul22 | Jul23 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | -0.10 | -0.72 | 0.72 | 0.17 | -0.08 |
PURE Bioscience Quarterly Data | ||||||||||||||||||||
Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
Change In Receivables | Get a 7-Day Free Trial | 0.10 | -0.03 | -0.10 | -0.06 | 0.18 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PURE Bioscience (OTCPK:PURE) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
PURE Bioscience's Days Sales Outstanding for the quarter that ended in Jan. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0.171 | / | 0.326 | * | 91 |
= | 47.86 |
2. In Ben Graham's calculation of liquidation value, PURE Bioscience's accounts receivable are only considered to be worth 75% of book value:
PURE Bioscience's liquidation value for the quarter that ended in Jan. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 0.557 | - | 2.407 | + | 0.75 * 0.171 | + | 0.5 * 0.074 |
= | -1.68 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of PURE Bioscience's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert F Bartlett | director | 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730 |
Bernard Blotner | director | 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730 |
Tom Y Lee | director | 1807 SAN GABRIEL BLVD., SAN GABRIEL CA 91776 |
David Rendall | director | 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730 |
Kristin Taylor | director | 13500 EVENING CREEK DRIVE N, SUITE 550, SAN DIEGO CA 92128 |
Dale Okuno | director | 35 N. ARROYO PARKWAY, SUITE 1, PASADENA CA 91103 |
Ivan Chen | director | 1725 GILLESPIE WAY, EL CAJON CA 92020 |
Thomas Richard Myers | officer: Chief Operating Officer | 1725 GILLESPIE WAY, EL CAJON CA 92130 |
Henry R. Lambert | director, officer: Chief Executive Officer | 1725 GILLESPIE WAY, EL CAJON CA 92020 |
Elisabeth Hagen | director | 1725 GILLESPIE WAY, EL CAJON CA 92020 |
Janet Risi Field | director | 9200 SOUTH DADELAND BOULEVARD, SUITE 800, MIAMI FL 33156 |
Franchise Brands, Llc | 10 percent owner | 325 BIC DRIVE, MILFORD CT 06461 |
Mark Stuart Elliott | officer: Vice President, Finance | 1725 GILLESPIE WAY, EL CAJON CA 92020 |
William Otis | director | 1725 GILLESPIE WAY, EL CAJON CA 92020 |
David M Theno | director | 1725 GILLESPIE WAY, EL CAJON CA 92020 |
From GuruFocus
By gurufocus 10qk • 03-17-2011
By gurufocus • 12-15-2008
By [email protected] insider • 06-23-2020
By gurufocus 10qk • 12-15-2010
By [email protected] insider • 06-18-2020
By GuruFocus Research GuruFocus Editor • 12-28-2020
By PRNewswire PRNewswire • 11-02-2022
By GuruFocus Research GuruFocus Editor • 06-30-2010
By gurufocus • 03-13-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.